

AD _____

Award Number: DAMD17-00-1-0039

TITLE: The Roles of the Y Chromosome Genes in Prostate Cancer

PRINCIPAL INVESTIGATOR: Yun-Fai Chris Lau, Ph.D.

CONTRACTING ORGANIZATION: Northern California Institute
for Research and Education
San Francisco, California 94121

REPORT DATE: February 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010724 058

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2001	3. REPORT TYPE AND DATES COVERED Annual (15 Jan 00 - 14 Jan 01)	
4. TITLE AND SUBTITLE The Role of the Y Chromosome Genes in Prostate Cancer			5. FUNDING NUMBERS DAMD17-00-1-0039	
6. AUTHOR(S) Yun-Fai Chris Lau, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northern California Institute for Research and Education San Francisco, California 94121 E-Mail: clau@itsa.ucsf.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) At present, information regarding the contribution of the men-only chromosome, the Y chromosome, to prostate cancer is lacking. The goals of this project are designed to address this question and to identify candidate genes on the Y chromosome involved in prostate cancer. The objectives are: 1) to study the expression of Y chromosome genes in prostate cancer and 2) to evaluate their effects in over-expression in the prostate of transgenic mice. In year 1, we completed the expression survey of all 31 functional genes on this chromosome. Results from this study identified the TSPY gene to potentially play a significant role in prostate cancer development and/or progression. For the next two years of the project, we plan to focus on an expression-function evaluation of TSPY and other Y chromosome genes using transgenic mouse approach, proposed under Objective 2. These studies will provide important information regarding the role of this male-specific chromosome on prostatic oncogenesis and in development of new diagnostic procedures, and/or treatment for this disease. In addition, the generation of transgenic mouse models of prostate cancer will be invaluable in understanding the disease mechanisms, therapeutic strategies and prevention of prostate cancer.				
14. SUBJECT TERMS Y chromosome, prostate cancer, transgenic mouse, animal models			15. NUMBER OF PAGES 33	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	9
Conclusions.....	9
References.....	10
Appendices.....	11

INTRODUCTION

The role of the Y chromosome in prostate cancer has been debated on numerous occasions (see reference 1 for review). Both a gain and a loss of this chromosome had been reported in the literature, suggesting the possible existence of an oncogene and tumor suppressor gene respectively. In the past, studies on the function of the Y chromosome in oncogenesis of male-specific organs, such as the prostate gland and testis, are limited due to the lack of information on the genetic content of this chromosome. Recent advances in positional cloning and Human Genome Project have identified most of genes postulated to be on this chromosome, thereby providing the necessary resource for detailed studies on the contribution of Y chromosome genes to male-specific cancers, particularly on prostate cancer (2).

There are two objectives for the present project. First, we evaluate the potential roles of selected Y chromosome genes in prostate cancer by studying their expression patterns on a panel of prostate cancer samples with various degrees of malignancy. Results from these studies, together with information on the properties of the proteins encoded by the Y chromosome genes, should be helpful in determining the most likely candidate genes on this chromosome that may contribute to or be influenced by prostatic oncogenesis. Second, the function(s) of the most significant Y chromosome genes in prostate cancer will be evaluated using a regulated system for transgene expression using transgenic mouse strategies. We hope to correlate the expression-function of these Y chromosome genes to prostate cancer development and progression. These results will be compared to those of known oncogenes, such as the SV40 T antigen and/or c-Myc, expressed in the prostate. These studies should provide significant information on the possible role of the human Y chromosome in prostatic oncogenesis.

BODY

Task 1. To determine the expression/repression and function correlation between the Y chromosome genes and prostate cancer using immunohistochemistry and in situ mRNA hybridization techniques.

The goal of this task is to get a realistic assessment of the potential contribution of the Y chromosome genes in the development and progression of prostate cancer. Both immunohistochemistry and in situ mRNA hybridization techniques have been selected for these studies. Immunohistochemistry is most useful when specific antibodies are available. To this goal, we have generated specific antibodies against the protein products of two human Y chromosome genes, TSPY and SRY, and have obtained another specific antibody against the PHOG gene from Dr. Jay Ellison, Department of Pediatrics, Virginia Commonwealth University. A fourth antibody against a peptide of the mouse Zfy gene had also been generated in our laboratory. However, its cross-reactivity

to the human ZFY protein is limited, therefore we will not use this particular antibody for human ZFY expression study.

In situ mRNA hybridization technique is being used for the remainder of the Y chromosome genes selected for detailed expression studies. This technique does not require the generation of specific antibody, and is based on hybridization of specific probes to mRNA on the tissue sections. To accomplish this goal, we have amplified specific fragments of cDNAs from adult human testis RNA and prostate cancer tissues (2) and subcloned them in plasmid vectors using TA cloning technique. Currently, we have obtained recombinant clones containing the cDNA fragments for the EIF1AY, PRY, CSFR2A, IL3RA, DFFRY, DBY, UTY, TB4Y, SMCY, PRKY, MIC2, IL9R and RPS4Y genes (see 2 for description of genes). Through our previous work, we have also isolated full-length cDNAs for SRY, TSPY, ZFY and those for ANT3, XE7 and PHOG from Dr. Jay Ellison. This collection of Y chromosome gene cDNA probes will be useful in our subsequent expression studies using the in situ hybridization method.

Initially, we proposed to generate antisense and sense riboprobes for in situ mRNA hybridization experiments. However, our recent experience suggests that fresh probes are important for success in this procedure. Therefore, we will generate the respective probes from the above cDNA clones just prior to the actual experimentation. This will insure the integrity and specificity of the respective probes for the in situ mRNA experiments.

Currently, we have performed or initiated experiments on the immunohistochemistry and in situ mRNA hybridization studies on a panel of selected prostate specimens harboring BPH and/or prostate cancer with various Gleason grades. These studies include the TSPY, SRY and the PHOG genes. While these studies are in progress, we have also completed our initial survey of the expression of 31 functional Y chromosome genes on a panel of prostatic samples and cell lines in the presence and absence of hormonal stimulation (2). This study represents the first detailed study on the expression of all 31 functional genes, identified so far, on this male-specific chromosome. The results are significant in refining the course of our efforts for the next two years of this project, discussed later.

The TSPY Gene as a Significant Candidate Proto-Oncogene on the Y Chromosome

As a result of this initial study, one gene on the human Y chromosome has emerged to be the leading candidate that may participate or contribute to the oncogenic process in the prostate. This gene is the testis-specific protein Y encoded (TSPY) gene that was independently isolated in my laboratory several years ago. Since we had generated specific antibody against the recombinant protein of this gene, it was also the first Y chromosome gene that we had studied in details with in situ mRNA hybridization and immunohistochemistry.

Our study demonstrated that TSPY was heterogeneously expressed among the panel of prostatic samples, suggesting that its expression might be influenced by the disease conditions of the respective specimens. Further, TSPY expression was up-regulated by androgen stimulation in the responsive cell line, LNCaP. Using both in situ mRNA hybridization and immunohistochemistry, we demonstrated that TSPY was preferentially expressed in cancerous epithelial cells. The results from these two procedures were in agreement with each other.

TSPY has been mapped on the critical region of the human Y chromosome postulated to harbor a gene(s) that predisposes the dysgenetic gonads of XY sex-reversed females to develop gonadoblastoma. These XY females have lost their functional sex determining gene, SRY, but have retained some Y chromosome materials (including TSPY) in their respective genome (1,3). Among the 5 genes identified within this region for the gonadoblastoma locus on the Y chromosome (GBY), TSPY is the leading candidate since others are either non-functional or have additional copies residing outside this GBY critical region. The GBY gene serves a vital function in the testis, but when it is inappropriately expressed in the germ cells of gonads in a female environment, it predisposes the gonads to develop tumor. Using a specific antibody against the human TSPY protein, we had performed immuno-staining studies on four gonadoblastoma. The results from these studies were exciting and demonstrated a preferential expression of TSPY in tumor germ cells of all gonadoblastoma samples examined (3). We had expanded this study to include two cases of testicular seminoma which also showed a preferential and elevated expression of this gene in tumor germ cells. These findings supported the candidacy of TSPY as the gene for GBY. Further, together with the results of the expression studies on prostate cancer samples (described above) the observations implied that this GBY candidate gene may play an important role in other male-specific cancers, such as seminoma and prostate cancer.

Task 2. To generate animal models for the functional evaluation of Y chromosome genes in prostate cancer

The long-term goal of this task is to establish an efficient system to evaluate the contribution of the most significant Y chromosome gene(s), identified under Objective 1, to prostatic oncogenesis. To achieve this Objective, we implement the Tet-Off transgene regulation system in transgenic mice (4) to construct various transgenic mouse models for prostate cancer. In this regulatory system, there are two types of transgenic mice harboring either a transactivator or a responder transgene respectively. Mice harboring either of these genes will be normal. However, when they are crossed with each other to generate bi-transgenic mice harboring both the transactivator and responder transgenes in their genomes, the transactivator gene can stimulate a high level expression of the responder gene. Such a transactivation can be abolished or suppressed by administering a harmless antibiotic, tetracycline or doxycycline, to the animals via their drinking water. Hence, one can compare the physiology and/or oncogenic conditions of genetically identical animals either over-expressing or repressing the responder gene. Any differences between the two groups can be attributed to the over-expression of

the responder transgene. In our case, we will use the candidate Y chromosome gene as a responder gene whose expression is the subject of investigation. We use a prostate-specific promoter, such as that for the rat probasin (PB) (5) or the human PSA gene (6,7), to direct the expression of the transactivator (tTA) gene in the prostate gland, thereby targeting the transactivation of the Y chromosome gene primarily in this organ.

For the past year, we were able to construct the basic transactivator genes directed by the rat probasin promoter, PB-tTA, and the human PSA promoter, PSA-tTA. For the responder gene, we have constructed a basic vector, pTIG, in which the green fluorescent protein (EGFP) can be co-expressed with the responder gene in the same transcriptional unit. We have successfully inserted independently the cDNAs for TSPY, SRY, and SV40 T antigen in this vector, designated as pTIG-TSPY, pTIG-SRY and pTIG-TagΔ respectively.

Next, we tested the ability of these vectors to transactivate a known responder gene, such as TRE-Luc, or to respond to an established transactivator, such as the CMV-tTA, in cell culture system. For PSA-tTA transactivator, we co-transfected it with the TRE-Luc responder gene in LNCaP cells and determined the responses of the luciferase gene in the presence or absence of doxycycline in the culture media. The results showed that PSA-tTA gene was capable of transactivating the luciferase responder gene in the absence of doxycycline. Such response was abolished when doxycycline was included in the media. We were also able to demonstrate that such transactivation was greatly increased when androgen was administered to the cells. Androgen responsiveness of the PSA promoter had been well-documented (6,7). For the responder genes, we evaluated them using a HeLa cell line that had been permanently transfected with a constitutively expressed transactivator (CMV-tTA) gene. When the responder gene, e.g. TIG-TSPY, was transfected transiently to the HeLa Tet-off cells, both the green fluorescent protein and TSPY were transactivated by the endogenous tTA gene to high levels which were repressed in the presence of doxycycline. We detected the GFP and TSPY expression by direct microscopic observation and Western blotting of transfected cells respectively. These experiments established the functionalities of these constructs and paved the way for transgenic mouse construction.

Using the above constructs, we had initiated our transgenic mouse experiments by embryo microinjection in our own laboratory. So far, we had generated a total of 8 transgenic lines harboring the PB-tTA transactivator, 1 line for the PSA-tTA transactivator, and 7 lines for TIG-TSPY responder. Currently, these lines are being maintained and used to establish breeding colonies and homozygous lines. Most recently, we have initiated the construction of transgenic mice for the SV40 T antigen responder gene, TIG-TagΔ. Once established, they will be used to generate bi-transgenic animals harboring a prostate-specific transactivator and the appropriate responder for the proposed studies.

FUTURE DIRECTIONS

The next funding period, we plan to continue the studies proposed in our original proposal. However, recognizing the importance of transgenic mouse models for prostate cancer and the time-consuming procedure on mouse husbandry, we plan to emphasize the studies proposed under Objective 2 for the remainder of the project. For the expression survey of the Y chromosome genes described in Objective 1, we believe we have achieved its goal using a combination of immunohistochemistry and in situ mRNA hybridization (the original methods of choice) and semi-quantitative RT-PCR approach (additional method). We have now analyzed the prostatic expression of all 31 functional genes, so far identified on the human Y chromosome. The most important of these studies identified the TSPY gene to be a potential oncogene in prostate cancer, in addition to it being the candidate gene for GBY. Hence, this important clue must be followed up with detailed molecular, cellular and transgenic mouse studies to elucidate the mechanism(s) by which TSPY may mediate prostatic oncogenesis. This important result from studies conducted under Objective 1 necessitates the immediate emphasis of work proposed under Objective 2.

TSPY encodes a protein with a highly conserved domain homologous to many cyclin B binding proteins (8). This important observation suggests that TSPY may exert its oncogenic properties through modulation of the cell cycle progression in tumorigenic prostatic cells. Such modulation may also be influenced by the hormonal microenvironment of the prostate gland. There are several interesting questions to address. Does over-expression of TSPY in cells stimulate cell proliferation and/or minimizing apoptosis? Does TSPY indeed bind to cyclin B? If so, at what stage of the cell cycle does it exert its effects? Does over-expression of TSPY in the prostate of transgenic mice promote cancer development in this organ? How do its effects compare to those of other known oncogenes, such as the SV40 T antigen, c-Myc or H-Ras? For the remaining two years, we hope to conduct studies proposed in Objective 2 and provide some answers to these important and exciting questions on the role of TSPY and Y chromosome genes in prostatic oncogenesis.

KEY RESEARCH ACCOMPLISHMENTS

- Conduct detailed studies on the expression of all 31 functional Y chromosome genes in prostate cancer and cell lines.
- Identify TSPY to be a putative proto-oncogene residing on the human Y chromosome.
- Establish several transgenic mouse lines harboring either the transactivator or the responder gene, thereby laying the necessary foundation for constructing an efficient system to evaluate the contribution of not only the candidate Y chromosome genes, but also candidates from other human chromosomes, in prostatic oncogenesis.

REPORTABLE OUTCOMES

- First detailed study on the expression of all functional genes, isolated so far, on the human Y chromosome in prostate cancer. This report provides the clues for further studies on the contribution of the Y chromosome to prostate cancer.
Lau Y-FC and Zhang J (2000). Expression analysis of thirty-one Y chromosome genes in human prostate cancer. *Molecular Carcinogenesis* 27:308-321.
- Identification of TSPY as a significant candidate gene for the gonadoblastoma gene on the Y chromosome. This study demonstrates the elevated levels of expression of TSPY in gonadoblastoma and testicular seminoma, suggesting a role for this gene on the oncogenesis of respective organs.
Lau Y-FC, Chou PM, Iezzoni JC, Alonzo JA and Komuves LG (2001). Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. *Cytogenetics and Cell Genetics*, in press.
- Demonstration of a preferential and elevated expression of TSPY on prostate cancer. This study establishes the potential universal role of TSPY in male-specific cancers, emphasizing on prostate cancer.
Lau Y-FC and Komuves LG (2001). Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. In revision.

CONCLUSIONS

Studies conducted in the first year of this project have provided significant information regarding the roles of Y chromosome genes in prostatic oncogenesis. Through a combination of immunohistochemistry, in situ mRNA hybridization and incorporation of the quantitative RT-PCR technique, we completed a preliminary survey on the expression patterns of all 31 functional Y chromosome gene in prostate cancer and cell lines. This survey had identified the TSPY gene to be a strong candidate for a cancer predisposition locus, GBY, on the human Y chromosome and to play a significant role in prostate cancer.

For the next two years, we plan to emphasize on studies under Objective 2 of the proposal and focus on elucidating the mechanisms by which TSPY and other Y chromosome genes may exert their efforts on tumorigenesis of the prostate gland. These studies will also provide important animal models of prostate cancer.

SO WHAT

The studies should be valuable in our fight against prostate cancer. The identification of a Y chromosome gene, TSPY, as a candidate oncogene in prostate cancer may be important for developing new strategies/procedures for diagnosis, pathological grading and clinical prognosis of prostate cancer.

The availability of transgenic mouse models of reversible prostate cancer will greatly facilitate further investigation on the etiology of and the evaluation of therapeutic strategies for prostate cancer in men.

REFERENCES

1. Lau, Y-FC (1999). Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. *Am J Hum Genet*, 64:921-927.
2. Lau Y-FC and Zhang J (2000). Expression analysis of thirty-one Y chromosome genes in human prostate cancer. *Mol Carcin* 27:308-321.
3. Lau Y-FC, Chou PM, Iezzoni JC, Alonzo JA and Komuves LG (2001). Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. *Cytogenetics and Cell Genetics*, in press.
4. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujard H (1995). Transcriptional activation by tetracyclines in mammalian cells. *Science* 268:1766-1769.
5. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML and Matusik RJ (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. *Lab Invest* 78:319-333.
6. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG and Henderson DR (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. *J Biol Chem*, 271:7043-7051.
7. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW and Trapman J (1997). A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen in humans. *Mol endocrinol*, 11:1256-1265.
8. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A and Grosveld G (1992). Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. *Mol Cell Biol*, 12:3346-3355.

Expression Analysis of Thirty One Y Chromosome Genes in Human Prostate Cancer

Yun-Fai Chris Lau* and Jianqing Zhang

Division of Cell and Developmental Genetics, Department of Medicine, VA Medical Center, 111C5, University of California, San Francisco, San Francisco, California

Rapid advances in positional cloning studies have identified most of the genes on the human Y chromosome, thereby providing resources for studying the expression of its genes in prostate cancer. Using a semiquantitative reverse transcription–polymerase chain reaction (RT–PCR) procedure, we had examined the expression of the Y chromosome genes in a panel of prostate samples diagnosed with benign prostatic hyperplasia (BPH), low and/or high grade carcinoma, and the prostatic cell line, LNCaP, stimulated by androgen treatment. Results from this expression analysis of 31 of the 33 genes, isolated so far from the Y chromosome, revealed three types of expression patterns: i) specific expression in other tissues (e.g., *AMELY*, *BPY1*, *BPY2*, *CDY*, and *RBM*); ii) ubiquitous expression among prostate and control testis samples, similar to those of house-keeping genes (e.g., *ANT3*, *XE7*, *ASMTL*, *IL3RA*, *SYBL1*, *TRAMP*, *MIC2*, *DBY*, *RPS4Y*, and *SMCY*); iii) differential expression in prostate and testis samples. The last group includes X–Y homologous (e.g., *ZFY*, *PRKY*, *DFFRY*, *TB4Y*, *EIF1AY*, and *UTY*) and Y-specific genes (e.g., *SRY*, *TSPY*, *PRY*, and *XKRY*). Androgen stimulation of the LNCaP cells resulted in up-regulation of *PGPL*, *CSFR2A*, *IL3RA*, *TSPY*, and *IL9R* and down regulation of *SRY*, *ZFY*, and *DFFRY*. The heterogeneous and differential expression patterns of the Y chromosome genes raise the possibility that some of these genes are either involved in or are affected by the oncogenic processes of the prostate. The up- and down-regulation of several Y chromosome genes by androgen suggest that they may play a role(s) in the hormonally stimulated proliferation of the responsive LNCaP cells. *Mol. Carcinog.* 27:308–321, 2000. © 2000 Wiley-Liss, Inc.

Key words: Y chromosome; gene expression; prostate cancer

INTRODUCTION

The human Y chromosome harbors a small number of genes that play essential and critical roles in the determination, differentiation, and maintenance of male specific organs, such as the testis and prostate gland. Recent positional cloning studies have isolated most of the small number of genes postulated to reside on the human Y chromosome [1–4]. These advances have provided invaluable resources for defining the functions of this chromosome in both normal and diseased physiology of the male-specific organs. Currently, 33 genes have been isolated from this chromosome and they can be divided into three groups (Table 1). The first group consists of X–Y identical genes located on the two pseudoautosomal regions (PARs). PAR1 is located on the telomere of the short arm while PAR2 is situated on the telomere of the long arm. PAR1 and PAR2 contain approximately 2.6 Mb and 400 kb of DNA, respectively. PAR1 harbors 10 genes and PAR2 has two genes. Each PAR gene has an identical gene on the corresponding PARs of the X chromosome. The second group consists of 10 X–Y homologous, but not identical, genes located on the nonrecombining region of the human Y chromosome (NRY). They are single-copy genes and most of which are ubiquitously expressed in many human tissues, including the prostate. Except the amelo-

genin Y (*AMELY*) gene that codes for an enamel protein, the functions of these genes are still largely unknown. Further, it is still uncertain whether these X and Y homologues are interchangeable in their functionality. The third group has 11 members that are specific to the human Y chromosome. The sex determining region Y (*SRY*) gene has been demonstrated to be the testis determining factor (TDF) that switches on testis differentiation pathway during embryogenesis [5]. Functions of the remaining 10 Y-specific genes have not been defined. Most of them consist of multiple copies on the Y chromosome and express in the testis. They are postulated to serve some functions in male-specific organs, such as regulation of spermatogenesis in the testis [6].

The role of the human Y chromosome in prostate cancer has not been investigated in details. Most studies utilized either classical or molecular cytogenetic techniques but molecular studies on individual genes on this chromosome have been lacking. So far, only the expression patterns of two genes,

*Correspondence to: Dr. Chris Lau, Division of Cell and Developmental Genetics, Department of Medicine, VA Medical Center, 111C5, University of California, San Francisco, 4150 Clement Street, San Francisco, CA 94121. E-mail: clau@itsa.ucsf.edu

Received 11 August 1999; Revised 13 October 1999; Accepted 28 October 1999

Table 1. Genes on the Human Y Chromosome*

Gene symbol	Gene name	Comments
Group 1: X-Y identical genes		
Pseudoautosomal region 1—short arm		
<i>PGPL</i>	pseudoautosomal GTP-binding protein-like	A conserved GTP-binding protein gene, closest to the telomere of the short arm of sex chromosomes
<i>SHOX/PHOG</i>	short stature homeo-box/pseudoautosomal homeo-box-containing osteogenic gene	A homeo-box containing gene involved in bone growth and stature. Postulated to contribute to Turner phenotype
<i>XE7</i>	XE7	A gene identified from an inactive-X cDNA library, nuclear located product
<i>CSFR2A</i>	GM-CSF receptor 2, alpha subunit	A receptor gene for the granulocyte-macrophage colony stimulating factor, a growth and differentiation factor
<i>IL3RA</i>	Interleukin 3 receptor alpha subunit	A cytokine receptor gene sharing homology to <i>CSFR2A</i> gene, IL3 binds to its receptors and promotes hematopoietic cell proliferation
<i>ANT3</i>	adenine nucleotide translocase	A member of the ADP/ATP translocase family, involved in cellular energy metabolism
<i>ASMTL</i>	ASMT-like	A gene encoding a putative fusion protein that shares homology with the bacterial <i>maf/orfE</i> at its amino end and to ASMT at its carboxyl terminus
<i>ASMT</i>	acetylserotonin methyltransferase	Coding for an enzyme involved in the last step of melatonin synthesis
<i>TRAMP</i>	TRAMP	A single-exon gene encodes a protein with homology to transposases of the Ac family
<i>MIC2</i>	MIC2	coding for a surface antigen detected by a monoclonal antibody, 12E7. (M, monoclonal; IC, Imperial Cancer Research Fund; 2, order of discovery)
Pseudoautosomal region 2—long arm		
<i>IL9R</i>	Interleukin 9 receptor	Receptor for a growth factor for T cells, erythroid and myeloid precursor cells
<i>SYBL1</i>	synaptobrevin-like 1	Coding for a synaptobrevin-like protein
Group 2: X-Y homologous genes		
Non-recombining Y region—short arm		
<i>RPS4Y</i>	ribosomal protein S4 Y isoform	Ribosomal protein gene postulated to be involved in Turner syndrome; X homologue, <i>RPS4X</i>
<i>ZFY</i>	zinc finger Y	Coding for a nuclear transcription factor harboring a DNA-binding domain with 13 zinc fingers, X-homologue, <i>ZFX</i>
<i>PRKY</i>	protein kinase Y	PRKY and its X homologue, <i>PRKX</i> , are members of cAMP-dependent serine/threonine protein kinase superfamily
<i>AMELY</i>	amelogenin Y	Expressed only in developing tooth buds. X-homologue, <i>AMELX</i> . Possibly related to tooth size locus
Non-recombining region—long arm		
<i>DFFRY</i>	Drosophila fat facets related Y	Homologous to <i>Drosophila</i> deubiquinating enzyme required for eye development and oogenesis. X homologue, <i>DFFRX</i>
<i>DBY</i>	dead box Y	Coding for a protein homologous to RNA helicases harboring conserved DEAD (Asp-Glu-Ala-Asp) motifs
<i>UTY</i>	ubiquitous TPR motif Y	Coding for a protein containing TPR motifs, implicated in protein-protein interaction and as a H-Y antigen
<i>TB4Y</i> <i>SMCY</i>	thymosin β 4 Y isoform selected mouse cDNA Y	X homologue sequesters actin Human homologue of the mouse <i>Smcy</i> gene coding for a minor histocompatibility H-Y antigen and may serve as a spermatogenic factor
<i>EIF1AY</i>	Translation initiation factor 1A	X homologue is an essential translation initiation factor

Table 1. (Continued)

Gene symbol	Gene name	Comments
Group 3: Y-specific genes		
Non-recombining region—short arm		
<i>SRY</i>	sex determining region Y	Evolutionary conserved gene coding for the testis determining factor (TDF)
<i>TSPY</i>	testis-specific protein Y-encoded	Repeated gene coding for a putative cyclin-B binding protein homologous to that of oncogene, <i>SET</i> . Postulated to direct the spermatogonial cells to enter meiosis and to be involved in oncogenesis of the testis tumors and gonadoblastoma.
<i>PRY</i>	PTP-BL related Y	Coding for a protein homologous to PTP-BL, a putative protein tyrosine phosphatase, also repeated on the long arm
<i>TTY1</i>	testis transcript Y1	Repetitive transcripts without any protein coding sequences, also present on the long arm
<i>TTY2</i>	testis transcript Y2	Repetitive transcripts without any protein coding sequences, also present on the long arm
Non-recombining region—long arm		
<i>BPY1</i>	basic protein Y1	Coding for a 125-residue basic protein, repeated gene
<i>BPY2</i>	basic protein Y2	Coding for 106-residue basic protein, repeated gene
<i>CDY</i>	chromodomain Y	Coding for a protein with chromodomain and putative catalytic domain, may modify DNA/protein during spermatogenesis, repeated gene
<i>XKRY</i>	XK related Y	Coding for a protein homologous to XK, a membrane transporter protein, repeated gene
<i>RBM</i>	RNA binding motif	Repeated gene coding for a RNA binding protein, a candidate for the azoospermia factor (AZF)
<i>DAZ</i>	deleted in azoospermia	A gene coding for another RNA binding protein, a candidate for the azoospermia factor (AZF)

*See references 1–4,30 for detailed description of genes on the human Y chromosome and information on additional references.

CSF2RA coding for the α subunit of the GM-CSF receptor and *MIC2* coding for a cell surface antigen, on PAR1 [7], and two Y-specific genes, *SRY* and *ZFY*, had been studied in both prostate adenocarcinoma and benign prostatic hypertrophy (BPH) [8,9]. To initiate a survey of expression patterns of these Y chromosome genes, we have developed an experimental strategy to study the expression of a large number of genes in representative prostate samples and prostatic cell lines. Results from this study identify several Y chromosome genes that are either aberrantly expressed in prostate samples and/or regulated by androgen treatment in the responsive prostatic cell line, LNCaP. This survey hence has identified several candidate genes on the Y chromosome that may either play a role(s) in or be influenced by prostatic oncogenesis.

MATERIALS AND METHODS

Tissues, Cell Lines and RNA Preparation

Tissue biopsies were obtained from the Cooperative Human Tissue Network, Western Division at Cleveland. The prostate samples include one benign prostatic hyperplasia (BPH), two BPHs with cancer foci, and three prostate cancer specimens with

various degrees of malignancy (Table 2). Their classifications were based on pathological examination of parallel preparations from the respective samples by attending pathologists of the Institute of Pathology at Cleveland. Since the prostate gland contains various amounts of epithelia and stroma, it is conceivable that normal epithelial cells and stromal elements might be present within the cancerous epithelia and vice versa in these samples. Two prostatic cell lines, LNCaP and PC3, were included in the analysis and they were obtained from the American Type Culture Collection. These cell lines cause tumor formation when they are injected into nude mice. The LNCaP cell line is androgen responsive and can be stimulated by male hormone treatment while PC3 is androgen non-responsive under the same conditions [10,11]. Three testis samples (two normal and one atrophic) were also included as references. Total RNAs were purified from respective tissues and cell lines according to a standard procedure by using the Trizol Reagent (GIBCO-BRL). Purified RNAs were treated with RNase-free RQ1-DNase (Promega Inc.) according to the manufacturer's protocol, phenol-chloroform extracted, precipitated with ethanol, and stored in DEPC-treated water at -20°C .

Table 2. Human Tissue Samples

Samples	Diagnosis
Testes	
1. Normal testis	25 year old from autopsy
2. Normal testis	34 year old with atrophic testis and chronic epidymitis
3. Atrophic testis	40 year old with seminoma on left testicle, uninvolved right testicle with atrophy
Prostates	
4. BPH	72 year old, BPH, no patient information
5. BPH + CA	69 year old, adenocarcinoma, Gleason's score 3 + 2 = 5, 25% CA, 50% NEO of remainder
6. BPH + CA	55 year old, Gleason's score, 3 + 2 = 5, 25% CA + 100% BPH on remainder
7. CA	66 year old, % CA unavailable, Gleason's score 3 + 4 = 7
8. CA	61 year old, infiltrating prostate cancer, Gleason's score 3 + 5 = 8, 100% CA in Tumor, 20% NEO of remainder
9. CA	69 year old, prostate cancer, 10% CA of tumor 90% NEO of remainder, other information unknown
Cell lines	
10. LNCaP (androgen responsive)	
11. PC3 (androgen nonresponsive)	
Control	
12. Blank	

CA, cancer; NEO, neoplasm; BPH, benign prostatic hyperplasia.

LNCaP and PC3 cells were cultured in RPMI1640 and Ham F-12 media, respectively, supplemented with 10% fetal bovine serum. They were grown at 37°C in a 5% CO₂ atmosphere. For androgen treatment, LNCaP cells were seeded at 2×10^6 cells per 150 mm culture dish and were cultured for 7 d in RPMI1640 medium supplemented with 10% charcoal-dextran treated (hormone-depleted) fetal bovine serum. The cells were then cultured separately for additional 9 d in the same medium supplemented with a synthetic androgen, R1881, at 0, 10^{-10} , 10^{-9} , or 10^{-8} M concentration. The culture media were changed every 2–3 d. The cells were then harvested for RNA preparation by using the Trizol Reagent (GIBCO-BRL) and RQ1-DNase digestion, as before.

RT-PCR Analysis

PCR primer sets were designed from cDNA sequences of 31 of the 33 genes from the Y chromosome retrieved from the GenBank database [1,2]. Table 3 shows the primer sets for 31 Y chromosome genes and five reference genes. The primers for the repetitive sequences, *TTY1* and *TTY2* were omitted. Their transcripts do not contain any protein-coding capability and were not studied in details here. In the cases of X-Y homologous genes, the respective primer sets were designed to be specific for only the Y-located alleles according to available sequence information. The primers were designed to amplify cDNA fragments of 400–600 bp

in size and from the 3' end of the respective transcripts of the Y chromosome genes. cDNAs were synthesized with 2 µg of total RNAs from the respective samples by using a Superscript II cDNA synthesis kit (GIBCO-BRL). Five percents of the cDNA products were amplified with the respective primer sets in 25 µL of reaction buffer by using the High Fidelity PCR kit (Roche Biochemicals). The touchdown PCR conditions were: 1 × 95°C, 5 min; 2 × (95°C, 30 s; 60°C, 30 s; 72°C, 90 s), 2 × (95°C, 30 s; 58°C, 30 s; 72°C, 90 s), 2 × (95°C, 30 s; 56°C, 30 s; 72°C, 90 s), 2 × (95°C, 30 s; 54°C, 30 s; 72°C, 90 s), 35 × (95°C, 30 s; 52°C, 30 s; 72°C, 90 s), and 72°C, 10 min. The reactions were performed in a multiplexing format on a 96-well microtiter dish by using the PTC-100 Programmable Thermal Control (MJ Research Inc.). Eleven samples and one blank control were arranged along the horizontal row for each Y chromosome gene. For a 96-well format, eight Y chromosome genes were analyzed. The touchdown procedure allowed PCR primer sets of different annealing temperatures to be used in the same time [12–13]. Fifteen microliter of the amplified products were then analyzed by electrophoresis in a 1.2% agarose gel, and visualized by ethidium bromide staining. For the relative expression levels of the Y chromosome genes in LNCaP cells under different hormonal treatments, the last round of amplification was adjusted to 20, 25, 30, or 35 cycles, depending on the relative abundance of the respective Y chromosome gene transcripts in the

Table 3. Primer Sets Used for RT-PCR Analysis

Gene	Primers	Sequences (5' to 3')
Y chromosome genes		
Pseudoautosomal regional—X-Y identical genes		
<i>PGPL</i>	PGPL-3	CGAGGTCCACCTTGTGTGAAC
	PGPL-5	CATCATGGGGTCAGGAGAATCC
<i>SHOX/PHOG</i>	SHOX-3	CGACAAGAGCAAACTCCATCTG
	SHOX-5	AGGACCACGTAGACAATGACAAGG
<i>XE7</i>	XE7-3	GGAGCATCAGACCATTITGTACCAD
	XE7-5	CAGCGTACTTGGCACTTCAGTTTC
<i>CSFR2A</i>	CSFR2A-3	ATGTCCATGCCATTCTTACACC
	CSFR2A-5	TTCAACCCTCCAGCAATGTC
<i>IL3RA</i>	IL3RA-3	ATTACACAGGCATCTCCCATGC
	IL3RA-5	AACCTCCTTCCAGCTACTCAATCC
<i>ANT3</i>	ANT3-F	CACCAAGTCCGACGGCATCCG
	ANT3-G	ACGGTTGAGGATTCTACGTGG
<i>ASMTL</i>	ASMTL-3	TGGGAGGTCAAACACAGTCACC
	ASMTL-5	GATATTGCCAGCAAAGTGGACG
<i>ASMT</i>	ASMT-3	CAATTACCAGAATGCCACCACC
	ASMT-5	AGGAAGGAACCACTACCTGGAGAC
<i>TRAMP</i>	TRAMP-3	TGAAGAGAACGCTGGCAATGCTAC
	TRAMP-5	GCTTTCAGTCATTCAGGGAAACAC
<i>MIC2</i>	MIC2-3	CTCGGTGGGGTTGACATTG
	MIC2-5	CACAGGAAAGAGGGGAAGAGG
<i>IL9R</i>	IL9R-1	TGGAGCCCTTGCTGAGACTGAAC
	IL9R-2	AGCTCTCAGTTTCTGGAGCAAGG
<i>SYBL1</i>	SYBL1-3	GAGTTGACTGCTGACCGTATTCG
	SYBL1-5	TGTCGCCGCTAGTCTTATGAGC
Nonrecombining region—X-Y homologous genes		
<i>RPS4Y</i>	RPS4Y-1	AACCTCGGTCGTGTTGGTGTGATC
	RPS4Y-2	GCTGCTACTGCAATTTAGCCACTG
<i>ZFY</i>	ZFY-3	CATCAGCTGAAGCTTGTAGACACACT
	ZFY-5	ATTGTCTTAAGTCGCCATATCTCT
<i>PRKY</i>	PRKY-R	AAAACAGACAACATAAAATTACA
	PRKY-F	GACCTTTTCTTCACGTGAC
<i>AMELY</i>	AMELY-6	TGGCTGCACCAACCAATCATC
	AMELY-7	GTGAGGCTGTGGCTGAAC
<i>DFFRY</i>	DFFRY-3	GGTGTAAGTACAAAAGATGGGCTC
	DFFRY-5	CCAGCAGCACATCACCTTGAACAAC
<i>DBY</i>	DBY-3	GCATTACTGAGCCAACAGGACATC
	DBY-5	AGGATTTGGTGCCAGAGACTATCG
<i>UTY</i>	UTY-3	GGTATGTTGAAGTTGGTGGTCTTG
	UTY-5	CAGATGCTGTTCCAGTCTAACC
<i>TB4Y</i>	TB4Y-3	GCTATTTTCTTCCCTGCCAGC
	TB4Y-5	GGTGTGCGCTCTTTTCTGTGG
<i>SMCY</i>	SMCY-3	AAGTACATAAAGAGGGTGGTGGGG
	SMCY-5	GCTTACAACACAAGGATTCAGGCTC
<i>EIF1AY</i>	EIF1AY-3	CGAGGCACAAAGGATGAAAAGG
	EIF1AY-5	GGTCTACAGTTGGGATTTGGC
Nonrecombining region—Y-specific genes		
<i>SRY</i>	(Set A) SRY mid-3	TCTTCGGCAGCATCTTCGCC
	SRY mid-5	TCGCGATCAGAGGCGCAAGA
	(Set B) SRY-coding3	GGTCTTTGTAGCCAATGTTA
	SRY-coding5	ATGCAATCATATGCTTCTGC
<i>TSPY</i>	TSPY4-3	CCTTGAGAATGTTATTTTTCATTG
	TSPY4-5	CAGATGTCAGCCCTGATCACTG
<i>PRY</i>	PRY-3	TCCAATCAACGCCTCTCCTTTC
	PRY-5	GGTTATCTTCAAGTGCCTCGGAC
<i>BPY1</i>	BPY1-3	CCTAACTTAGTTGCTGCTCAGGG
	BPY1-5	CGAAGAAGAAGACTACCAAGGTGG

Table 3. (Continued)

Gene	Primers	Sequences (5' to 3')
<i>BPY2</i>	BPY2-3	GCATTACCCAGTTTTGTCAGTCAG
	BPY2-5	CCAGATTTTCACAGGTGCTGCTTAC
<i>CDY</i>	CDY-3	GATCGTCAGTGGATTTTGAGCC
	CDY-5	GGTTCCAAACCCCTTATACGACC
<i>XKRY</i>	XKRY-3	GAAGCGGAGCTTAAAGCCAAAG
	XKRY-5	GCATTGCTGATGACATATCCCTC
<i>RBM</i>	YRRM-13	TACTTTGGTCTTTTCTG
	YRRM-14	ATGATGGCTACGGTGAG
<i>DAZ</i>	DAZ-1	GGAGCAAAGGAGAAATCTGTGGAC
	DAZ-2	TCAAACCCAGCAACTTCCCATG
Reference genes		
Androgen receptor		
<i>AR</i>	AR-3	GTTTCCAATGCTTCACTGGGTG
	AR-5	ACCAATGTCAACTCCAGGATGC
Prostate specific antigen		
<i>PSA</i>	PSA-3	CAGTCCCTCTCCTTACTTCATCCC
	PSA-5	GCACCCCTATCAACTCCCTATTG
<i>SET</i>	SET-3	AGCTGAGTCCATTATCCACCCAG
<i>SET</i>	SET-5	CGCACTTTTGCAGGATGACCTC
Uridine diphosphoglucuronosyltransferase		
<i>UGT</i>	UGT-3	TCTCCAAATGCTATCCTTCCCC
	UGT-5	TCTGGATTGAGTTGTCATGCG
Hypoxanthine-guanine phosphoribosyl transferase		
<i>HPRT</i>	HPRT-A	CCTGCTGGATTACATTAAAGCACTG
	HPRT-B	GTCAAGGGCATATCCAACAACAAAC

LNCaP cells. The number of cycles was determined empirically for each gene. Such adjustments ensured a semilinear amplification of each Y chromosome gene. The resulting PCR products were analyzed similarly in 1.2% agarose gels. The Φ X174 RF DNA digested with HaeIII was used as molecular weight markers. The PCR primers of several Y chromosome genes, such as *TSPY*, *RBM*, and *DAZ*, spanned across one or several introns in their respective structural genes. In all cases, PCR amplification of the cDNA samples did not reveal any products specific for the respective genomic DNAs, suggesting that the RQ-DNase treatment was effective in eliminating any contaminant DNA in the original RNA preparations. Hence, all signals obtained from the touchdown RT-PCR analysis were derived from the respective Y chromosome gene transcripts.

Northern Blotting

Twenty microgram of total RNAs from respective LNCaP cells stimulated with the synthetic androgen, R1881, at different dosages were processed for northern hybridization, as described before [25]. cDNA fragments from RT-PCR amplification were subcloned into plasmid vector by using a TA

Cloning kit (Invitrogen Inc.) and confirmed by single-pass sequencing with an ABI automated sequencer (DNA Sequencing Core Lab, Howard Hughes Medical Institute). The respective inserts were excised from the plasmids and labeled with a random prime labeling kit (Roche Biochemicals) in the presence of ^{32}P - α -dCTP (Amersham Inc.) and used as probes in the northern hybridization procedure. Hybridization signals were visualized by X-ray autoradiography.

RESULTS

To establish an expression-function correlation, we had developed a strategy for identifying potentially important Y chromosome gene(s) involved in prostate oncogenesis. In this approach, a semiquantitative reverse transcription and touchdown PCR assay [12,13] was used to analyze the expression of Y chromosome genes in a panel of representative prostate and testis samples. cDNAs were initially synthesized from total RNAs of prostate and testis samples and subjected to PCR amplification with respective gene-specific primers in a multiplex format. The touchdown procedure utilized an initial high annealing temperature that was gradually ramped down at decreasing intervals, thereby

allowing primer sets of different T_m to anneal to the correct sequences in the respective samples. For a 96-well microtiter dish, one could examine a total of 11 samples and one blank control (along the horizontal row) for eight gene primer sets (along vertical column). The RNA samples were derived from specimens with different clinical stages or cells under various culture conditions. This strategy, hence, allowed a rapid preliminary evaluation on the expression of a large number of specific genes on a panel of tissue/cell samples.

Expression of Y Chromosome Genes in Normal and Diseased Prostates

Of the 31Y chromosome genes examined, specific PCR products were obtained from the respective gene transcripts (Figure 1A–D). Genes residing on the pseudoautosomal regions were either expressed uniformly (e.g., *PGPL*, *ASMTL*, *IL3RA*, *ANT3*, *XE7*, *MIC2*, and *SYBL1*) or minimally (e.g., *SHOX/PHOG*, *CSFR2A*, and *IL9R*) (Figure 1A). These expression patterns confirmed their ubiquitous and tissue-specific expression, respectively. However, we did observe slightly higher levels of expression of *PGPL* and *CSFR2A* in the prostate cancer samples (#7–9) than in the BPH samples (#4–6). Further, we could not rule out the possibility that these tissue-specific growth factors and receptor genes, i.e., *PHOG*, *CSFR2A*, *IL3RA*, and *IL9R*, might be aberrantly expressed in other forms, e.g., metastatic, prostate cancer, or under androgen stimulation, (discussed below). The expression patterns of the X-Y homologous genes were more complex (Figure 1B). The *RPS4Y*, *DBY*, and *SMCY* genes were expressed relatively uniformly while the remaining six X-Y homologous genes were expressed variably among samples of the testis, prostate, and prostatic cell lines. There seemed to be relatively higher RT-PCR products for *ZFY*, *PRKY*, and *DDFRY* among the prostate cancer specimens (#7–9) than those among the BPH samples (#4–6) while the reverse was observed for *EIF1AY*. Presumably, these X-Y homologous genes are expressed in most human tissues [2]. Our results demonstrated that their levels of expression could vary between tissues and among samples of the same tissue. Their variability might reflect the physiological states of the respective tissues or samples.

The Y chromosome-specific genes are present only in the male genome and do not have any homologue and/or equivalent genes in the female genome. They are postulated to serve vital functions in male specific organs, such as male sex determination and regulation of spermatogenesis [5,6]. Initially all these genes were demonstrated to be expressed specifically in the testis [2]. Indeed, transcripts from *CDY* and *RBM* genes were primarily detected in the testis (Figure 1C). Both *RBM* and *CDY* had been postulated to serve some functions in

spermatogenesis, their testis specific expression was reasonably expected. Apart from their expression in LNCaP cells, the *BPY1* and *BPY2* genes also exhibited a testis-specific pattern. They encode two small basic proteins of unknown functions. The expression levels of the remaining five genes in the testis and prostate samples were heterogeneous (Figure 1C), suggesting that they might represent aberrant expression patterns in these tumor tissues and cell lines. Several aberrant RT-PCR fragments were observed in PC3 cell line. Subsequent cloning and sequencing of these aberrant fragments, however, showed that they were not derived from transcripts of corresponding Y-specific genes. Similar analysis of the gene-specific fragments from other testis and prostate samples confirmed their origins from respective Y chromosome gene transcripts. The lack of Y-specific gene products in PC3 cells might reflect the fact that cytogenetic analysis had failed to reveal an intact Y chromosome in this cell line [11]. The detection of RT-PCR products from both pseudoautosomal and X-Y homologous genes in this cell line (Figure 1B) suggests that perhaps part of this chromosome might have been retained (or translocated to other chromosomes) in its genome. PCR amplification of genomic DNA isolated from PC3 cells indeed showed positive products from selected PAR, e.g., *ANT3*, *IL3RA*, and *SYBL1*, and X-Y homologous genes, e.g., *ZFY*, *DDFRY*, *DBY*, and *AMELY* (data not shown). However, we still cannot rule out the possibility that the RT-PCR products might be derived from transcripts of the respective X alleles or homologues.

Five reference genes, androgen receptor (*AR*) [14], prostate specific antigen (*PSA*) [15], oncogene *SET* [16], uridine diphosphoglucuronosyltransferase (*UGT*) [17] and hypoxanthine phosphoribotransferase (*HPRT*) were analyzed similarly with the touch-down RT-PCR technique by using respective gene-specific primers. The results indicated that both *PSA* and *SET* genes were expressed almost evenly in all prostate samples and the LNCaP cells (Figure 1D). The *AR* expression varied among the samples while that for *UGT* was predominantly in the LNCaP cell line. In particular, *UGT* gene was down-regulated upon androgen stimulation in this cell line [17]. Most testis and prostate RNA samples seemed to be of good quality, as indicated by their relatively uniform signals for *HPRT* (Figure 1E). The PC3 cells had been demonstrated to lack functional *AR* and *PSA* [10,11]. However, recent reports had documented the presence of the respective genes and residual expression of both androgen receptor and *PSA* molecules in PC3 cells [10,11,43,44]. The detection of both *AR* and *PSA* transcripts with the highly sensitive RT-PCR technique here confirmed the low-level expression of these genes in this androgen-insensitive prostatic cell line.




Figure 1. Expression of Y chromosome genes in testis and prostate samples and prostatic cell lines. A. X-Y identical genes on the pseudoautosomal regions. B. X-Y homologous genes on the nonrecombining region of the Y chromosome (NRY). C. Y-specific genes on NRY. D. Reference genes and E. HPRT. The + signs indicate RNA samples treated with reverse transcription, the - signs indicate

RNA samples without reverse transcription, before PCR. See Table 2 for samples description and Table 1 and 3 for gene designations and primer information respectively. M = DNA fragments from Φ X174 RF DNA digested with Hae III. The fragments are 1353, 1078, 872, 603, 310, 271-281, 234, 194, 118, 72 bp from top to bottom.

In summary, this initial survey of Y chromosome gene expression in prostate tissues (BPH, BPH + CA, and CA) and prostatic cell lines (androgen responsive and independent) suggested that genes on this chromosome could be divided into several cate-

gories. The first category of genes consisted of tissue-specific genes, such as *AMELY*, *SHOX/PHOG*, and *IL9R*. Their expression in prostate tissues was minimal, if detected. Genes for the second category were expressed almost uniformly in most prostate




Figure 1. (Continued)

tissues (of different pathological classification). They most likely serve essential, and presumably normal, functions in this organ. Members of this category were derived primarily from X-Y identical (PAR), such as *ANT3*, *XE7*, and *MIC2*, and X-Y homologous genes, such as *RPS4Y*, *DBY*, and *SMCY*. The third category of genes consisted of mostly Y-specific and X-Y homologous genes. Their expression levels varied from sample to sample. These genes, particularly the Y-specific ones, are most interesting since their expression patterns may reflect the oncogenic conditions of the prostate samples and cell lines examined.

Androgen Regulation of Y Chromosome Genes

We used the relatively quantitative touchdown RT-PCR technique to evaluate the regulation of Y chromosome genes in the hormonally responsive LNCaP cell line. LNCaP cells were initially cultured

in hormone-depleted media. A synthetic androgen, R1881, was then added to the media in different flasks, with concentrations of 10^{-10} , 10^{-9} , and 10^{-8} M. The cells were cultured for an extended period of nine days before they were harvested for total RNA preparation. Numerous studies had demonstrated that similar R1881 treatments stimulate the proliferation of LNCaP cells in a dosage dependent manner [9-11]. The RNA samples from untreated controls and cells treated with R1881 were analyzed with the touchdown RT-PCR procedure by using gene-specific primer sets, as described. Results from this experiment indicated that only a few Y chromosome genes were affected by hormonal treatment of the cells (Figure 2A-D). They include the *IL9R*, *PGPL*, *CSFR2A*, *IL3RA*, *TSPY*, *SRY*, *ZFY*, *PRY* genes. The steady state transcripts from *TSPY*, *PGPL*, *CSFR2A*, *IL3RA*, and *IL9R* genes increased while those of *SRY*, *ZFY*, and *PRY*




Figure 2. Androgen regulation of Y chromosome gene expression in LNCaP cells, cultured with 0 (control), 10^{-10} , 10^{-9} and 10^{-8} M of synthetic androgen, R1881. A. X-Y identical genes and HPRT control. B. X-Y homologous genes on NRY. C. Y-specific genes on NRY. D. Reference genes. The steady state transcripts from *ZFY*, *SRY*, and *PRY* on the Y chromosome and *AR* and *UGT* reference genes were down regulated while those for *IL9R*, *PGPL*, *CSFR2A*, *IL3RA*, *TSPY*, and *PSA* were up regulated upon androgen treatment of LNCaP cells.

decreased in LNCaP cells by R1881 treatments. The down regulation seemed to be extreme for the *SRY* gene. At a small dose of 10^{-10} M of the androgen, the *SRY* product (Primer A) was totally undetectable while those from the other Y gene transcripts were easily observed. To confirm these results, the PCR amplification was repeated with a second set of *SRY* primers (Primer B). Again, PCR products from

androgen treated cells were drastically reduced (Figure 2C). Parallel PCR analysis of other Y chromosome genes, e.g., *XKRY*, *XE7*, *ANT3*, *DBY*, and *RPS4Y*, showed uniform amplification of the respective products.

Transcript levels for the five reference genes, *HPRT*, *AR*, *PSA*, *SET*, and *UGT*, were analyzed similarly in the LNCaP cells. The *PSA* gene showed




Figure 3. Northern blotting analysis of *PSA*, *UGT*, and *TSPY* transcripts in LNCaP cells treated with the synthetic androgen, R1881. *PSA* and *TSPY* steady state transcripts increased and those for *UGT* decreased under androgen stimulation of LNCaP cells.

a gradual increase while *UGT* and *AR* genes showed gradual decreases of their respective transcripts upon R1881 treatments (Figure 2D). Both *HPRT* and *SET* genes showed no apparent response to androgen regulation. Previously, *UGT* expression had been demonstrated to be down-regulated with androgen treatments in this prostatic cell line [17]. Northern blotting analysis of RNAs from the respective LNCaP cell populations indeed showed increases in steady state transcripts of both *PSA* and *TSPY* genes and a decrease of *UGT* transcripts (Figure 3). Although there was a general correlation between the RT-PCR and northern hybridization results, the relative amounts of transcripts for these genes detected by northern blotting were not as linear as those detected by RT-PCR (e.g., Figure 2). These differences may be attributed to the sensitivity of the respective methods.

DISCUSSION

Prostatic carcinogenesis is a multi-step process mediated by many genetic and environmental components. One or a few of the genetic components could be derived from genes on the Y chromosome. Unfortunately, the assessment on the contribution of this chromosome to the etiology of prostate cancer has been difficult, although the Y chromosome is absolutely essential for male development, including organogenesis of the testis and the prostate gland. There are two main reasons that may be attributed to this problem. First, major portion of this chromosome does not pair with the X chromosome and does not go through any meiotic recombination, thereby making any linkage analysis to be extremely difficult, if not impossible. Consequently, most of the genetic linkage studies on families with hereditary prostate cancer had

excluded the Y chromosome in their analyses [48–51]. Second, both classical cytogenetic and/or chromosome painting studies documenting either a gain or a loss of this chromosome in tumor cells derived from prostate cancer [52–55] were relatively crude and did not provide any specific information on the individual Y chromosome genes in the samples analyzed. These results contributed to the controversy regarding the role of this chromosome in prostate cancer. Recently, Tricoli [56] argued that many studies utilizing samples from either short-term cultures and/or tissue sections might give rise to clonal cell selection and nuclear truncation, respectively. He suggested that the Y chromosome was present in most of the prostate cancer specimens. To demonstrate his point, Tricoli [56] had studied the status of the Y chromosome on touch preparations from 42 fresh prostate tumors by using chromosome painting technique. The touch preparation allowed him to transfer intact epithelial tumor cells directly onto a slide without paraffin or frozen sectioning procedures. Results from Tricoli's study demonstrated a gain of the Y chromosome in a single sample and normal number of Y chromosome in the remaining 41 samples, suggesting that loss of the Y chromosome is an infrequent event in prostate cancer. This study, if confirmed independently, supports Tricoli's postulation that this male-specific chromosome is present in the prostate during its oncogenic process. Further, there is genetic evidence suggesting that first-degree males (i.e., father, son, or brother) of a prostate cancer patient who have the same Y chromosome might have a higher probability of getting the disease than those without a first-degree male suffering from prostate cancer [45–47]. These observations, taken together, signify that the genes on this male chromosome might play some roles in prostatic carcinogenesis. Indeed, a cancer locus, termed gonadoblastoma on the Y chromosome or GBY, has long been mapped on the human Y chromosome [57,58]. The GBY locus harbors a gene(s) that predisposes the dysgenetic gonads of XY females to develop gonadoblastoma at a high (>30%) frequency. Significantly, recent isolation of most of the genes residing on the human Y chromosome [1–4] has presented a panel of candidate genes that may play some roles in cell growth, cell cycle regulation, and signal transduction (Table 1). Mutations and/or aberrant expression of one or a few of these genes may contribute to the oncogenic processes not only in gonadoblastoma but also in male-specific organs, including the testis and the prostate gland.

Previous studies had demonstrated the expression of both *SRY* and *ZFY* in over 60% of 30 BPH and prostate cancer samples [7,8]. The present study confirms a similar level (four of six samples) of expression for both genes among the prostatic samples analyzed. In addition, we have further

demonstrated that these two genes, as well as *PRY*, were down-regulated in LNCaP cells upon androgen treatments. *SRY* has been demonstrated to be the gene for *TDF* responsible for switching a male development during embryogenesis [5]. Although the exact mechanism(s) by which *SRY* mediates sex determination is uncertain, a repressor mode of action has been proposed [23]. Its function in adult tissues is still uncertain. If *SRY* serves as a repressor for cell growth or proliferation, its down-regulation would be needed for cellular proliferation events. *ZFY* encodes a transcription factor with DNA-binding zinc fingers [24]. It has a homolog, *ZFX*, on the X chromosome. Both *ZFY* and *ZFX* genes have distinct expression patterns different from each other [25]. The *Zfx* gene in the mouse may play a role in germ cell development since male and female mice harboring a null *Zfx* gene on their X chromosome showed reduced numbers of germ cells in their respective sex organs [26]. *PRY* is a recently isolated repeat gene on the human Y chromosome. It encodes a protein homologous to the protein tyrosine phosphatase, *PTP-BL* [2,27]. Significantly, protein kinases and phosphatases have been postulated to be regulators and signal transducers in cell growth and proliferation [28]. The down-regulation of *PRY* suggests a possible involvement of this putative tyrosine phosphatase in androgen stimulation of LNCaP cells.

Androgen plays an essential role in the development and differentiation of prostate in embryos and prostate cancer pathogenesis in adults. Androgen regulates the expression of genes via the androgen receptor activation pathway [18–22]. Many of these androgen-regulated genes are growth factors and extracellular matrix components that act specifically on the epithelial cells and stimulate their proliferation and differentiation. It has been argued that a similar, if not the same, set of genes may be involved in the regulation of normal development of the embryonic prostate and in oncogenesis of the adult prostate. Although the Y chromosome has been demonstrated to be critical in switching on testis determination and differentiation during embryogenesis [5], its role in prostate development has not been clearly defined. Thus, the identification of androgen-regulated expression of any of the Y chromosome genes would suggest potential candidates important for both prostate organogenesis and oncogenesis.

The present study indeed has identified several PAR genes, *PGPL*, *CSFR2A*, *IL3RA*, *IL9R*, and the Y-specific gene, *TSPY*, to be up-regulated by androgen treatments in LNCaP cells. The *PGPL* gene encodes a putative small GTP-binding protein on the tip of the PAR1 [3]. Numerous studies have demonstrated that small GTPases, such as the Rho family, participate in various cytoskeletal organization and signaling processes and Ras-mediated cell transformation

[32–34]. If the *PGPL* product indeed can function as a GTPase, it may potentially play a similar role in cell signaling and transformation. The up-regulation of the three cytokine receptor genes, *IL9R*, *CSFR2A*, and *IL3RA*, suggests that cytokines and their receptors may play a role(s) in androgen-stimulated proliferation in this prostatic cell line. *IL9R* encodes the receptor for IL-9 [29] while *CSFR2A* and *IL3RA* encode the α subunits of receptors for the granulocyte-macrophage colony-stimulating factor (GM-CSF) and the IL-3, respectively [35–42]. Each α subunit exhibits specific affinity to the respective growth factor but requires heterodimerization with the β subunit to form a fully functional receptor [35–38]. Recent studies have demonstrated that GM-CSF and its receptors are expressed in prostatic cell lines LNCaP, PC3, and DU-145 [39–41]. Further recombinant human GM-CSF stimulates proliferation of the LNCaP cells in vitro [40], suggesting that prostatic cells are responsive to this hematopoietic factor. GM-CSF mediates the proliferative function through its receptor that induces phosphorylation events in the LNCaP cells [40]. Immunostaining experiments localized both α and β subunits of the GM-CSF receptor on the epithelial cells of normal prostate, BPH, and prostatic carcinoma. Both subunits are expressed at low level in normal human prostatic tissue, at substantial level in BPH, and at prominent level in prostatic carcinoma [40]. Hence, GM-CSF and its receptor may play a role in prostatic cell proliferation and oncogenesis. The cytokines, IL3, IL9, and their receptors have been demonstrated to play a role(s) in T cell and other hematologic malignancies [42], their roles in prostatic cells are still unknown.

Using a mRNA differential display technique, Shen and colleagues [7] had recently identified *MIC2* to be a gene up-regulated by androgen treatment of LNCaP cells. *MIC2* expression was responsive to androgen stimulation in the parental LNCaP line, but not in sublines with higher metastatic potential. Immunostaining experiments detected the *MIC2* encoded product, E2, in tissues from patients with primary prostate cancer, but only sporadically in benign prostatic hyperplasia tissues. Our results confirmed that *MIC2* was expressed in mostly prostatic cancer and BPH tissues. However, its steady state RNA level was relatively uniform in LNCaP cells treated with various dosages of R1881. It is uncertain if the differences in our observations and those of Shen and colleagues [7] reflect the methodology and/or cell lines used in these studies.

The *TSPY* gene constitutes the most interesting gene on this chromosome whose aberrant and androgen-responsive expression may be involved in prostatic cell proliferation and oncogenesis in the prostate gland. *TSPY* is a repeat gene with about 20–40 copies on the human Y chromosome [see review, 30]. It is primarily located in the deletion interval 3

on Yp11.2, within a small region where the gonadoblastoma locus has been mapped on this chromosome [57–58]. Hence, *TSPY* is a candidate for *GBY* and whose expression has been demonstrated in gonadoblastoma tissues [30,58, Lau et al., unpublished observations]. *TSPY* protein shares extensive homology with that of the *SET* oncogene, involved in an intra-chromosomal translocation on chromosome 9 of a patient with undifferentiated acute leukemia [16]. *SET* is a member of a family of cyclin B-binding protein genes that includes the nucleosome assembly protein (*NAP-1*). Some members of this protein family are involved in cell cycle regulation. The *TSPY* gene is expressed normally in spermatogonial cells of the testis and has been hypothesized to direct these germ stem cells to proliferate and/or to enter meiosis [31]. Recently, aberrant expression of *TSPY* has been documented in testicular cancer samples, including germ seminoma and carcinoma-in-situ [30,31]. Our study showed that its expression in LNCaP cells could be stimulated by androgen treatments, suggesting that *TSPY* may be associated with the proliferative activities of these cells under such conditions.

The present survey of Y chromosome gene expression in prostate cancer and BPH samples has highlighted this portion of the human genome that is important for the normal differentiation and/or physiology of male-specific organs. Although there was no clear-cut pattern of Y gene expression specifically related to the degrees of malignancy in our specimens, a small number of genes, such as *TSPY*, *SRY*, *PRY*, *ZFY*, and the cytokine receptors, have been identified to play a potential role(s) in or to be influenced by oncogenesis in the prostate. These results, hence, form the basis for further studies using advanced techniques, such as in situ mRNA hybridization, immunohistochemistry, microdissection and RNA analysis, on clinically defined sets of specimens. Such investigations focusing on individual Y chromosome genes may provide significant insights into the likely contribution of this male-specific chromosome to the initiation and progression of prostate cancer.

ACKNOWLEDGMENT

This work was partially supported by grants from the NIH and VA Research and Development to YFCL. Y-FC Lau is a Career Research Scientist of the Department of Veterans Affairs.

REFERENCES

- Vogt PH, Affara N, Davey P, et al. Report of the Third International Workshop on Y Chromosome Mapping 1997. Heidelberg, Germany, April 13–16, 1997. *Cytogenet Cell Genet* 1997;79:1–20.
- Lahn BT, Page DC. Functional coherence of the human Y chromosome. *Science* 1997;278:675–680.
- Gianfrancesco F, Esposito T, Montanini L, et al. A novel pseudoautosomal gene encoding a putative GTP-binding protein resides in the vicinity of the X_p/Y_p telomere. *Hum Mol Genet* 1998;7:407–414.
- Esposito E, Gianfrancesco F, Ciccocioppa A, et al. A novel pseudoautosomal human gene encodes a putative protein similar to Ac-like transposases. *Hum Mol Genet* 1999;8:61–67.
- Goodfellow PN, Lovell-Badge R. *SRY* and sex determination in mammals. *Annu Rev Genet* 1993;27:71–92.
- Cooke HJ, Elliott DJ. RNA-binding proteins and human male infertility. *Trends Genet* 1997;13:87–89.
- Shen J, Zhou HE, Hursting SD, Chung LWK. Androgen regulation of the human pseudoautosomal gene *MIC2*, a potential marker for prostate cancer. *Mol Carcinog* 1998;23:13–19.
- Tricoli JV, Bracken RB. *ZFY* gene expression and retention in human prostate adenocarcinoma. *Genes Chrom Cancer* 1993;6:65–72.
- Tricoli JV, Yao JL, D'Souza SA, Bracken RB. Detection of sex-region Y (*SRY*) transcripts in human prostate adenocarcinoma and benign prostatic hypertrophy. *Genes Chrom Cancer* 1993;8:28–33.
- Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. *Prostate* 1996;29:386–394.
- Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. *Prostate* 1997;30:58–64.
- Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 'Touchdown' PCR to circumvent spurious priming during gene amplification. *Nucleic Acids Res* 1991;19:4008.
- Roux KH, Hecker KH. One-step optimization using touchdown and stepdown PCR. *Meth Mol Biol* 1997;67:39–45.
- Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. *Prostate* 1998;35:63–70.
- Young CY, Andrews PE, Tindall DJ. Expression and androgenic regulation of human prostate-specific kallikreins. *J Androl* 1995;16:97–99.
- von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. *Can*, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. *Mol Cell Biol* 1992;12:3346–3355.
- Belanger A, Hum DW, Beaulieu M, et al. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. *J Steroid Biochem Mol Biol* 1998;65:301–310.
- Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, et al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. *Mol Endocrinol* 1997;11:1256–1265.
- Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PV, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. *Mol Endocrinol* 1997;11:148–161.
- Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. *J Biol Chem* 1996;271:7043–7051.
- Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of *CDK2*, *CDK4*, and *CKI p16* genes. *Cancer Res* 1997;57:4511–4516.
- Trapman J, Cleutjens KB. Androgen-regulated gene expression in prostate cancer. *Semin Cancer Biol* 1997;8:29–36.

23. McElreavey K, Barbaux S, Ion A, Fellous M. The genetic basis of murine and human sex determination: a review. *Heredity* 1995;75:599-611.
24. Koopman P, Ashworth A, Lovell-Badge R. The ZFY gene family in humans and mice. *Trends Genet* 1991;7:132-136.
25. Lau YF, Chan KM. The putative testis-determining factor and related genes are expressed as discrete-sized transcripts in adult gonadal and somatic tissues. *Am J Hum Genet* 1989;45:942-952.
26. Luoh SW, Bain PA, Polakiewicz RD, et al. Zfx mutation results in small animal size and reduced germ cell number in male and female mice. *Development* 1997;124:2275-2284.
27. Hendriks W, Schepens J, Bachner D, et al. Molecular cloning of a mouse epithelial protein-tyrosine phosphatase with similarities to submembranous proteins. *J Cell Biochem* 1995;59:418-430.
28. Hunter T. The Croonian lecture. 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. *Philos Trans R Soc Lond B Biol Sci* 1998;353:583-605.
29. Demoulin JB, Renaud JC. Interleukin 9 and its receptor: an overview of structure and function. *Int Rev Immunol* 1998;16:345-364.
30. Lau YFC. Gonadoblastoma, testicular and prostate cancers and the TSPY gene. *Am J Hum Genet* 1999;64:921-927.
31. Schnieders F, Dork T, Arnemann J, Vogel T, Werner M, Schmidtke J. Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. *Hum Mol Genet* 1996;5:1801-1807.
32. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. *Oncogene* 1998;17:1415-1438.
33. Hotchin NA, Hall A. Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases. In: PJ Parker, T Pawson, editors. *Cell signaling* Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1996, p 311-322.
34. Khosravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. *Adv Cancer Res* 1998;72:57-107.
35. de Groot RP, Coffey PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. *Cell Signal* 1998;10:619-628.
36. Smith A, Metcalf D, Nicola NA. Cytoplasmic domains of the common beta-chain of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation or clonal suppression in myeloid leukaemic cell lines. *Embo J* 1997;16:451-464.
37. Baird PN, D'Andrea RJ, Goodall GJ. Cytokine receptor genes: structure, chromosomal location, and involvement in human disease. *Leukemia Lymphoma* 1995;18:373-383.
38. Goodall GJ, Bagley CJ, Vadas MA, Lopez AF. A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. *Growth Factors* 1993;8:87-97.
39. Savarese DM, Valinski H, Quesenberry P, Savarese T. Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. *Prostate* 1998;34:80-91.
40. Rivas CI, Vera JC, Delgado-Lopez F, et al. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. *Blood* 1998;91:1037-1043.
41. Rokhlin OW, Griebeling TL, Karassina NV, Raines MA, Cohen MB. Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface. *Anti-cancer Res* 1996;16:557-563.
42. Renaud JC, Kermouni A, Vink A, Louahed J, Van Snick J. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. *J Leuko Biol* 1995;57:353-360.
43. Katsuoka Y, Hoshino H, Shiramizu M, Sakabe K, Seiki K. Autoradiographic and cytochemical localization of androgen in human prostatic cancer cell lines. *Invest Urol* 1986;28:228-231.
44. Garde SV, Sheth AR, Porter AT, Pienta KJ. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. *Cancer Lett* 1993;70:159-166.
45. Bratt O, Kristoffersson U, Lundgren R, Olsson H. The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study. *Eur J Cancer* 1997;33:2237-2240.
46. Cussenot O, Valeri A, Berthon P, Fournier G, Mangin P. Hereditary prostate cancer and other genetic predispositions to prostate cancer. *Urol Int* 1998;60(suppl 2):30-34.
47. Glover FE Jr, Coffey DS, Douglas LL, et al. Familial study of prostate cancer in Jamaica. *Urol* 1998;52:441-443.
48. Ruijter E, van de Kaa C, Miller G, Ruiter D, Deruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. *End Rev* 1999;20:22-45.
49. Cooney KA, McCarthy JD, Lange E, et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. *J Natl Cancer Inst* 1997;89:955-959.
50. Dunsmuir WD, Edwards SM, Lakhani SR, et al. Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. *CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer* 1998;78:1430-1433.
51. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. *Nat Genet* 1998;20:175-179.
52. Brothman AR. Cytogenetic studies in prostate cancer: are we making progress? *Cancer Genet Cytogenet* 1997;95:116-121.
53. Multani AS, Ozen M, Agrawal A, Hopwood VL, von Eschenbach AC, Pathak S. Amplification of the Y chromosome in three murine tumor cell lines transformed in vivo by different human prostate cancers. *In Vitro Cell Dev Biol* 1999;35:236-239.
54. Geburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. *J Urol* 1997;157:223-227.
55. Konig JJ, Teubel W, van Dongen JW, Romijn JC, Hagemeijer A, Schroder FH. Loss and gain of chromosomes 1, 18, and Y in prostate cancer. *Prostate* 1994;25:281-291.
56. Tricoli JV. Y chromosome enumeration in touch preparations from 42 prostate tumors by interphase fluorescence in situ hybridization analysis. *Cancer Genet Cytogenet* 1999;111:1-6.
57. Page DC. Hypothesis: a Y-chromosomal gene causes gonadoblastoma in dysgenetic gonads. *Development* 1987;101(suppl):151-155.
58. Tsuchiya K, Reijo R, Page DC, Distche CM. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. *Am J Hum Genet* 1995;57:1400-1407.

Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma

Y.-F.C. Lau,^a P.M. Chou,^b J.C. Iezzoni,^c J.A. Alonzo,^d and L.G. Kömüves^a

Departments of ^aMedicine and ^dAnatomic Pathology, VA Medical Center, University of California, San Francisco CA; ^bDepartment of Pathology, Children's Memorial Hospital, Chicago IL; ^cDepartment of Pathology, University of Virginia Health Science Center, Charlottesville VA (USA)

Dedicated to Professor Dr Ulrich Wolf on the occasion of his retirement.

This work was partially supported by research grants from the National Institutes of Health, Department of Veterans Affairs and the Department of Defense Prostate Cancer Research Program (to Y.-F.C.L.). Y.-F.C.L. is a Senior Research Career Scientist of the Department of Veterans Affairs, USA.

Received 7 August 2000; manuscript accepted 17 August 2000.

Request reprints from Dr. Chris Lau, Division of Cell and Developmental Genetics, Department of Medicine, VA Medical Center, 111C5, 4150 Clement Street, San Francisco, CA 94121 (USA); telephone: (415) 476-8839; fax: (415) 750-6633; email: clau@itsa.ucsf.edu

Abstract. The gonadoblastoma locus on the Y chromosome (GBY) predisposes the dysgenetic gonads of XY females to develop in situ tumors. It has been mapped to a critical interval on the short arm and adjacent centromeric region on the Y chromosome. Currently

there are five functional genes identified on the GBY critical region, thereby providing likely candidates for this cancer predisposition locus. To evaluate the candidacy of one of these five genes, testis-specific protein Y-encoded (TSPY), as the gene for GBY, expression patterns of TSPY in four gonadoblastoma from three patients were analyzed by immunohistochemistry using a TSPY specific antibody. Results from this study showed that TSPY was preferentially expressed in tumor germ cells of all gonadoblastoma specimens. Additional study on two cases of testicular seminoma demonstrated that TSPY was also abundantly expressed in all stages of these germ cell tumors. The present observations suggest that TSPY may either be involved in the oncogenesis of or be a useful marker for both types of germ cell tumors.

Gonadoblastoma is a rare tumor that arises mostly in the dysgenetic gonads of phenotypic females who harbor some Y chromosome materials in their genome (Page, 1987). The tumor is composed of aggregates of primordial germ cells and sex cord elements resembling immature Sertoli and granulosa cells. These aggregates are surrounded by luteinized ovarian type stroma that may include Leydig or lutein-type cells (Scully, 1953, 1970). Gonadoblastoma has been considered to be an *in situ* germ cell malignancy from which invasive germ cell tumors can develop (Skakkebaek et al., 1987; Jorgensen et al., 1997; Looijenga and Oosterhuis, 1999; Heerbst et al., 1999).

The prevalence of gonadoblastoma among XY females had led David Page (1987) to hypothesize the presence of a locus, gonadoblastoma locus on the Y chromosome (GBY), that predisposes the dysgenetic gonads of these sex-reversed individuals to develop such *in situ* tumors. Page further predicted that the gene(s) encoded by the GBY locus has a normal function in the testis and acts as an oncogene only in the dysgenetic gonad. Using a panel of DNAs from XY females with gonadoblastoma, Page had initially mapped the GBY locus to deletion interval 3 on the short arm and intervals 4B-7 on the long arm of the Y chromosome. Additional studies further sublocalized this locus to a small region consisting of ~1-2 Mb of DNA in deletion intervals 3E-3G proximal to and 4B at the centromere and possibly 5E, a proximal interval on the long arm (Salo et al., 1995; Tsuchiya et al., 1995). Among the genes so far isolated from the human Y chromosome (Vogt et al., 1997; Lahn and Page, 1997; Lau and Zhang, 2000), there are five genes residing on this small region: amelogenin Y (AMELY), RNA binding motif Y (RBM Y), protein kinase Y (PRKY), protein tyrosine phosphatase PTP-BL related Y (PRY), and testis-specific protein Y-encoded (TSPY). Hence, they are candidates for GBY. AMELY encodes an enamel protein in the tooth buds (Salido et al., 1992). RBMY is a repeated gene with a majority of its functional members residing at interval 6 on the long arm, outside the GBY critical region (Cooke, 1999). It expresses a protein with RNA binding motif in the nuclei of male germ cells. PRKY is a single copy gene coding for a putative cAMP-dependent serine/threonine protein kinase (Schiebel et al., 1997). Both RBMY and PRKY have a homologous gene, RBMX and PRKX respectively, on the X chromosome (Schiebel et al., 1997; Delbridge et al., 1999). PRY is a recently isolated repeated gene family coding for a protein related to the PTP-BL tyrosine phosphatase (Lahn and Page, 1997). Some copies of PRY are present outside the GBY region. TSPY is a repeated gene whose functional members are primarily located in two clusters, TSPYA and TSPYB, within interval 3 (Zhang et al., 1992; Conrad et al., 1996; Vogt et al., 1997) on the short arm and as a single-copy on the proximal region

of the long arm (Ratti et al., 2000). TSPY shares tight homology to a family of cyclin B binding proteins, such as the SET oncoprotein and the nucleosome assembly protein (NAP-1) (Tsuchiya et al., 1995; Schnieders et al., 1996), and has been postulated to play a role in directing the spermatogonial cells to enter meiosis (Schnieders et al., 1996; Vogel et al., 1998). Other cyclin B binding proteins have been demonstrated to be involved in the mitotic process, cell proliferation and/or carcinogenesis (von Lindern et al., 1992; Adachi et al., 1994; Altman and Kellogg, 1997; Carlson et al., 1998; Shin et al., 1999). Hence, aberrant or inappropriate expression of TSPY in dysgenetic gonads may play a role in the etiology of gonadoblastoma.

To evaluate the candidacy of TSPY as the gene(s) for GBY, we have performed detailed expression analysis of TSPY in gonadoblastoma and testicular seminoma, or germ cell tumor, using immunohistochemical techniques. Our results demonstrate that TSPY is preferentially expressed in the germ cells of the tumor aggregates in gonadoblastoma and tumor cells at different stages of testicular seminoma. Its expression pattern is very similar to those of cyclin B1 and another cell proliferative marker, the proliferating cell nuclear antigen (PCNA). These findings, hence, support the postulation that TSPY is a significant candidate for GBY, and suggest a possible role of TSPY in the multi-step carcinogenesis of testicular seminoma.

Materials and methods

Patients

Tissue sections were obtained from archival formalin-fixed and paraffin-embedded tumor specimens. All three gonadoblastoma patients had previously been described (Iezzoni et al., 1997; Hussong et al., 1997). At the time of biopsies, Patient #1 was a 15-year old phenotypic female with a unilateral gonadoblastoma at the left gonad. Patient #2 was a 20-year old phenotypic female with bilateral gonadoblastoma. Both patients #1 and 2 have a 45,X/46, XY mosaic karyotype. Chromosome painting analysis on tissue sections of these tumors showed that most tumor cells harbored a Y chromosome while the stroma showed reduced numbers of cells harboring this chromosome (Iezzoni et al., 1997). Patient #3 was a 15-year old phenotypic female with a 46,XY karyotype. She developed a tumor mass on the left and a streak gonad on the right (Hussong et al., 1997).

Two testicular seminoma specimens were obtained from archival samples at the Anatomic Pathology Section, VA Medical Center, San Francisco. At the time of orchiectomy, Patient #1 was a 49-year old male with a tumor mass confined only to the left testicle. Pathological examination revealed a classical seminoma. Patient #2 was a 49-year old male with an advanced and mixed germ cell tumor composed of seminoma, embryonal carcinoma and yolk sac tumor.

Generation of a specific antibody against TSPY

The entire open reading frame of the human TSPY cDNA (Zhang et al., 1992) was subcloned in-frame in the *Eco*R1 site of the expression vector, pAR(Δ R1) (Blancar and Rutter, 1992), a derivative of the pET3a vector. Recombinant TSPY protein was synthesized in bacterial host, BL21DE3(pLysS) and purified by preparative SDS-PAGE from total lysates of induced bacterial culture. A polyclonal antiserum was generated by repeat immunizations of a New Zealand white rabbit using the service of a commercial vendor (Vancouver Biotechnology, Vancouver, Canada). The specificity of the antiserum was initially assayed by Western blotting against recombinant TSPY protein. The specificity of this antibody to TSPY was further confirmed by both Western blotting and immunocytochemical staining of HeLa cells expressing at high levels a transfected human TSPY gene (Lau, unpublished observations). A polyclonal antibody against the proliferative cell nuclear antigen (PCNA) was purchased from Dako Laboratory, Inc. (Carpinteria, CA). A polyclonal antibody against the human cyclin B1 (synthesized with a baculovirus vector in insect cells) was

a gift from Catherine Takizawa and David Morgan, Department of Physiology, UCSF. Both antibodies had previously been demonstrated to be specific for the respective antigens in Western blotting and immunostaining studies (Jin et al., 1998; Takizawa et al., 1999; Kömüves et al., 1999).

Immunohistochemistry of tumor tissue sections

Five micron sections were obtained from archival materials according to established procedure. Immunohistochemical staining was performed as previously described (Kömüves et al., 1999). Heat-induced antigen retrieval pre-treatment was utilized in procedures with PCNA and cyclin B1 antibodies. Immunostaining was conducted in a Tris buffer, pH 7.6, containing 4% of bovine serum albumin, 1% teleostean skin-gelatin, 0.1% Tween 20, and 500 mM NaCl. The primary antisera were used at 1:500 to 1:1000 dilution ratios. The binding of the primary antibody was detected by reaction with affinity-purified biotinylated goat anti-rabbit IgG, and visualized by either ABC-peroxidase or ABC-alkaline phosphatase reagents. Commercial substrate kits (Vector Laboratories, Burlingame, CA) were used for the enzymatic detections. For the brown and brick-red signals, the DAB and VECTOR NovaRED kits were used respectively with the ABC-peroxidase reagents. For the red signal, the VECTOR RED kit was used with the ABC-alkaline phosphatase reagents. All signals were dependent on the bindings of the respective primary antibodies and were independent of the substrate kits used. After the immunostaining, the sections were counter-stained with hematoxylin. Omitting the primary antibody in the procedure resulted in no signals. Preabsorption of the TSPY antiserum with excess recombinant TSPY protein abolished the staining. The sections were examined and recorded with a Zeiss Axiophot microscope.

Results

Preferential expression of TSPY in tumor germ cells of gonadoblastoma

Histological analysis of the gonadoblastoma specimens from all three patients showed characteristic aggregates of primordial germ cells and sex chord elements. Immunostaining of tissue sections of all four tumors (two patients with unilateral and one patient with bilateral tumors) showed positive staining of cancerous germ cells within these tumor aggregates of all three patients (e.g. Fig. 1A). In particular, the tumor of patient #3 was organized in smaller aggregates with less sex chord elements (Fig. 1B, C), partially resembling the morphology of some forms of germ cell tumors in the testis (e.g. Fig. 1L, M). The TSPY protein was prominently localized primarily in the cytoplasm of these large cells (Fig. 1C). In all cases, the sex cord elements and the stroma showed very little reactive signals (Fig. 1A, B). Mitotic cells were readily observed on specimens from this patient (Fig. 1D-I). Omission of the primary antibody or pre-absorption of the antiserum with excess recombinant TSPY protein abolished or greatly reduced the reactive staining of the germ cells in these procedures (e.g. Fig. 1I). Analysis of parallel sections with PCNA and cyclin B1 antibodies showed similar staining patterns as those with the TSPY antibody (data not shown). The signals were primarily located on the nuclei for PCNA while those for cyclin B1 seemed to be associated with both nuclei and cytoplasm of the germ cells. The general staining patterns indicated that TSPY, PCNA and cyclin B1 were co-expressed in the same tumor cells.

TSPY expression in the tumor cells at various stages of testicular seminoma

It has been argued that gonadoblastoma is a precursor form of more aggressive germ cell tumors (Skakkebaek et al., 1987; Jorgensen et al., 1997; Looijenga and Oosterhuis, 1999; Herbst et al., 1999). If TSPY is indeed the candidate for GBY, it would potentially participate in the oncogenic process of other germ cell tumors. Previously, Schneiders and

colleagues (1996) had indeed demonstrated an up-regulation of TSPY expression in in-situ carcinoma of the testis, a presumed precursor of germ cell tumors or seminoma. To address the question of whether TSPY may also play a role in more advanced testicular cancer, we have extended our study to include two cases of seminoma using the same immunohistochemical staining technique and specific antibodies against TSPY, PCNA and cyclin B1. They, together, showed various morphological forms potentially representing the different oncogenic stages of these tumors. At the early stages, spermatogenesis might have ceased, thereby depleting normal meiotic cells within the seminiferous tubules. In-situ carcinoma could also occur as a precursor during this initial carcinogenic period (Schnieders et al., 1996). The germ cell-depleted and epithelium-like tubules consisted of a single-layer of cells that might develop into localized multi-layer tumors at various peripheral segments (Fig. 1J, yellow arrows). This transformation progressed until most of the epithelia were lined with multiple layers of tumor germ cells (Fig. 1K). Invasive aggregates of cancerous germ cells eventually evolved from such tubular tumors, abandoning the original tubules (Fig. 1L, blue arrow). In the advanced stages, these aggregates could form a large tumor mass covering a sizable portion of the testis (Fig. 1L, N). Occasionally highly undifferentiated and loosely associated embryonal cells were observed in the late stages of these tumors (Fig. 1O). Presumably, these single tumor cells might have acquired some metastatic properties/potential. Significant expression of the TSPY protein was detected in the tumor germ cells at all stages of these testicular cancers (Fig. 1J-O). Similar to the expression pattern in gonadoblastoma, TSPY was primarily located on the cytoplasm of the tumor cells (Fig. 1M, O). Occasionally, nuclear locations of TSPY were also detected in a few cells. Under each microscopic view, a significant number of mitotic cells could easily be identified (white arrows, Fig. 1M, O). Similar to those in gonadoblastoma, most mitotic cells were stained positively with the TSPY antibody. TSPY expression was at a reduced or insignificant level in the interstitial regions of these testicular cancers.

Immunohistochemical staining of parallel tissue sections with PCNA and cyclin B1 antisera demonstrated similar expression patterns as that of TSPY for both antigens in testicular seminoma (data not shown). Again, PCNA showed a mostly nuclear location while cyclin B1 showed a nuclear and cytoplasmic staining pattern. These observations suggested a possible co-expression of these three proteins in the same tumor germ cells.

Discussion

The mapping of the GBY locus within a small region of the human Y chromosome suggests the existence of a proto-oncogene on this chromosome that predisposes the dysgenetic gonads of XY females to malignancy (Page, 1987; Salo et al., 1995; Tsuchiya et al., 1995). The identification of candidate genes for GBY will not only provide information on the molecular etiology of gonadoblastoma but will also shed light on the contribution of this chromosome to the carcinogenic processes of other male-specific cancers, such as testicular seminoma, germ cell tumors and prostate cancer (Looijenga and Oosterhuis, 1999; Lau, 1999; Lau and Zhang, 2000). Recent studies on TSPY have positioned it to be the most viable candidate for GBY within the critical region on the Y chromosome. First, it is present in the DNAs of gonadoblastoma patients (Salo et al., 1995; Tsuchiya et al.,

1995). Its transcripts had been detected by RT-PCR technique in the corresponding tumor tissues (Tsuchiya et al., 1995) and recently by immunostaining in a single case of gonadoblastoma (Hildenbrand et al., 1999). Second, immunostaining studies had demonstrated its expression in spermatogonia in normal testis (Schnieders et al., 1996), suggesting that TSPY may serve a normal function of directing the spermatogonial cells to enter meiosis, a condition for the GBY gene(s) initially postulated by David Page (1987). Third, the TSPY protein is highly homologous to a family of cyclin B binding proteins, including NAP-1 and SET oncoprotein (Tsuchiya et al., 1995; Schnieders et al., 1996), suggesting that it may bind to this mitotic cyclin and be involved in cell cycle regulation and/or cell proliferation (Shin et al., 1999). Results from the present study demonstrate that TSPY is preferentially expressed in the proliferating germ cells within the tumor aggregates in all four samples from three gonadoblastoma patients, further supporting the candidacy of TSPY for GBY.

Although TSPY protein has previously been detected in some forms of testicular tumors, including in-situ carcinoma (Schnieders et al., 1996), our study on the seminoma specimens has clearly demonstrated the high levels of expression of this GBY candidate gene in all stages of these advanced germ cell tumors. Hence, these results, together with those observed by others (Schnieders et al., 1996), establish a direct relationship between the aberrant TSPY expression and the oncogenic process of testicular cancer. Numerous studies have demonstrated that cyclin B binding proteins, such as SET, are either involved in oncogenesis of acute leukemia, Wilm's tumor or modulation of cell proliferation (von Lindern et al., 1992; Adachi et al., 1994; Carlson et al., 1998; Shin et al., 1999). Although the interactions between TSPY and cyclin B have yet to be demonstrated experimentally, the co-expression of these two molecules on the same tumor cells has raised the possibility that they may indeed interact in vivo. The present study has provided evidence supporting the hypothesis that aberrant expression of TSPY may lead to abnormal cell proliferation and tumor formation (Lau, 1999). Hence, TSPY is not only a key candidate for GBY but may also contribute to the oncogenesis of testicular seminoma.

Acknowledgements

We thank Angela Kwong and Jianqing Zhang for technical assistance.

References

- Adachi Y, Pavlakis GN, Copeland TD: Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. *J Biol Chem* 269:2258-2262 (1994).
- Altman R, Kellogg D: Control of mitotic events by Nap1 and the Gin4 kinase. *J Cell Biol* 138:119-130 (1997).
- Blanan MA, Rutter WJ: Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. *Science* 256:1014-1018 (1992).
- Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ: Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. *J Am Soc Nephrol* 9:1873-1880 (1998).

- Conrad C, Hierl T, Glaser B, Taylor K, Zeitler S, Chandley AC et al: High-resolution fluorescence in situ hybridization of RBM- and TSPY-related cosmid on released Y chromatin in humans and pygmy chimpanzees. *Chrom Res* 4:201–206 (1996).
- Cooke HJ: Y chromosome and male infertility. *Rev Reprod* 4:5–10 (1999).
- Delbridge ML, Lingenfelter PA, Disteché CM, Graves JA: the candidate spermatogenesis gene RBMY has a homologue on the human X chromosome. *Nature Genet* 22:223–224 (1999).
- Herbst H, Kuhler-Obbarius C, Lauke H, Sauter M, Mueller-Lantzsch N, Harms D et al: Human endogenous retrovirus (HERV)-K transcripts in gonadoblastomas and gonadoblastoma-derived germ cell tumors. *Virchows Arch* 434:11–15 (1999).
- Hildenbrand R, Schröder W, Brude E, Schepler a, König R, Sutte HJ, Arnemann J: Detection of TSPY protein in a unilateral microscopic gonadoblastoma of a Turner patient with a Y-derived marker chromosome. *J Pathol* 189:623–626 (?).
- Hussong J, Crussi FG, Chou PM: Gonadoblastoma: immunohistochemical localization of Mullerian-inhibiting substance, inhibin, WT-1, and p53. *Mod Pathol* 10:1101–1105 (1997).
- Iezzoni JC, Kap-Herr C, Golden WL, Gaffey MJ: Gonadoblastomas in 45,X/46,XY mosaicism: analysis of Y chromosome distribution by fluorescence in situ hybridization. *Am J clin Pathol* 108:197–201 (1997).
- Jin P, Hardy S, Morgan DO: Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. *J Cell Biol* 141:875–885 (1998).
- Jorgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE: Heterogeneity of gonadoblastoma germ cells: similarities with immature germ cells, spermatogonia and testicular carcinoma in situ cells. *Histopathology* 30:177–186 (1997).
- Körmüves LG, Hanley K, Jiang Y, Katagiri C, Elias PM, Williams ML et al: Induction of selected lipid metabolic enzymes and differentiation-linked structural proteins by air exposure in fetal rat skin explants. *J Invest Dermatol* 112:303–309 (1999).
- Lahn BT, Page DC: Functional coherence of the human Y chromosome. *Science* 278:675–680 (1997).
- Lau Y-F, Zhang J: Expression analysis of 31 Y chromosome genes in human prostate cancer. *Mol Carcin* 27:308–321 (2000).
- Lau Y-F: Gonadoblastoma, testicular and prostate cancers, and the *TSPY* gene. *Am J hum Genet* 64:921–927 (1999).
- Looijenga LH, Oosterhuis JW: Pathogenesis of testicular germ cell tumours. *Rev Reprod* 4:90–100 (1999).
- Page DC: Hypothesis: a Y-chromosomal gene causes gonadoblastoma in dysgenetic gonads. *Development* 101 Suppl:151–155 (1987).
- Ratti A, Stuppia L, Gatta V, Fogh I, Calabrese G, Pizzuti A, Palka G: Characterization of a new TSPY gene family member in Yq (TSPYq1). *Cytogenet Cell Genet* 88:159–162 (2000).
- Salido EC, Yen PH, Koprivnikar K, Yu LC, Shapiro LJ: The human enamel protein gene amelogenin is expressed from both the X and the Y chromosomes [see comments]. *Am J hum Genet* 50:303–316 (1992).
- Salo P, Kaariainen H, Petrovic V, Peltomaki P, Page DC, de la Chapelle A: Molecular mapping of the putative gonadoblastoma locus on the Y chromosome. *Genes Chrom Cancer* 14:210–214 (1995).
- Schiebel K, Mertz A, Winkelmann M, Glaser B, Schempp W, Rappold G: FISH localization of the human Y-homolog of protein kinase PRKX (PRKY) to Yp11.2 and two pseudogenes to 15q26 and Xq12→q13. *Cytogenet Cell Genet* 76:49–52 (1997).
- Schnieders F, Dork T, Arnemann J, Vogel T, Werner M, Schmidtke J: Testis-specific protein, Y-encoded (*TSPY*) expression in testicular tissues. *Hum Mol Genet* 5:1801–1807 (1996).
- Scully RE: Gonadoblastoma. A review of 74 cases. *Cancer* 25:1340–1356 (1970).
- Scully RE: Gonadoblastoma: a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. *Cancer* 6:445–463 (1953).
- Shin KS, Shin EY, Bae SC, Kim SR, Jeong GB, Kwak SJ et al: Expression of SET is modulated as a function of cell proliferation. *J Cell Biochem* 74:119–126 (1999).
- Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J: Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. *Int J Androl* 10:19–28 (1987).
- Takizawa CG, Weis K, Morgan DO: Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. *Proc natl Acad Sci, USA* 96:7938–7943 (1999).

- Tsuchiya K, Reijo R, Page DC, Disteché CM: Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. *Am J Hum Genet* 57:1400-1407 (1995).
- Vogel T, Dittrich O, Mehraein Y, Dechend F, Schnieders F, Schmidtke J: Murine and human TSPYL genes: novel members of the TSPY-SET-NAP1L1 family. *Cytogenet Cell Genet* 81:265-270 (1998).
- Vogt PH, Affara N, Davey P, Hammer M, Jobling MA, Lau YF et al: Report of the Third International Workshop on Y Chromosome Mapping 1997. Heidelberg, Germany, April 13-16, 1997. *Cytogenet Cell Genet* 79:1-20 (1997).
- von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. *Mol Cell Biol* 12:3346-3355 (1992).
- Zhang JS, Yang-Feng TL, Muller U, Mohandas TK, de Jong PJ, Lau YF: Molecular isolation and characterization of an expressed gene from the human Y chromosome. *Hum Mol Genet* 1:717-726 (1992).

Fig. 1. Immunohistochemical localization of TSPY in gonadoblastoma and testicular seminoma. (A) TSPY was primarily located in the germ cells of tumor aggregates of all three gonadoblastoma patients. This figure illustrates an example of immunostaining on sections from Patient #1. (B) Patient #3 harbored a gonadoblastoma with less organized aggregates. (C) An enlargement of boxed area in B, showing prominent cytoplasmic locations of the TSPY protein. (D-I) Examples of mitotic cells within the gonadoblastoma from patient #3. Cells in D-G were stained with TSPY antibody; H with PCNA antibody and I a control without primary antibody reaction. (J-O) Immunostaining of TSPY on tumor sections from seminoma at early (J), intermediate (K) and late (L-O) stages of the testicular cancer. Yellow arrows in J point to possible localized tumor growth areas. Blue arrow in L indicates a tubule being abandoned by the invasive growth of the tumor (boxed area enlarged in M). N Shows an advanced tumor area consisting of large mass of tumor cells and highly undifferentiated and loosely associated embryonal cells (boxed area enlarged in O). White arrows in M and O point to mitotic tumor cells. Positive signals are brick red in A; chocolate in B and C; brown in D-H; and red in J-O. Bars indicate 50 µm in A, C, M and O; 200 µm in B, J, L, and N; and 10 µm in D-I.

Note added in proof. Recently Stuppia et al. (2000) have demonstrated by cloning and sequence analysis that PRY gene spans 25 kb in size and contains 5 exons. The functional copies of PRY are located in interval 6 on Yq while those on Yp retain only exon 1 and 2 and are likely non-functional.

Stuppia L, Gatta V, Gaspari A, Grande R, Morizio E, Fantasia D, Mingarelli R, Calabrese G, Palka G: Molecular characterization of PRY and TTY2 on the human Y chromosome. *Am J Hum Genet* 67(Supl2):185 (2000).

